One-year results from the FUTURE-II trial
A decade already passed from the first use of bioresorbable vascular scaffold in percutaneous coronary interventions. The first studies - by using surrogate endpoints - showed some superiority of BRS vs. metallic drug-eluting stent in terms of the so-called vascular restoration therapy with recovery of vasomotion and vascular pulsatility when the scaffold was absorbed.
Nevertheless, after these first promising findings, larger and randomized clinical trials and subsequent meta-analyses, powered to hard clinical endpoints, showed that bioresorbable vascular scaffolds, made ...







